Table 3.
Scenario analyses.
| Group | C ($) | Incr C | E (QALY) | Incr E | ICER($/QALY) |
|---|---|---|---|---|---|
| Time horizons of 15 years | |||||
| R-CHOP | 32684.70 | 7.47 | |||
| Pola-R-CHP | 64276.48 | 31591.79 | 8.29 | 0.82 | 38640.28 |
| Time horizons of 20 years | |||||
| R-CHOP | 33717.13 | 8.89 | |||
| Pola-R-CHP | 65204.06 | 31486.94 | 10.42 | 1.54 | 20477.62 |
| Decreased price by 50% of polatuzumab vedotin | |||||
| R-CHOP | 31015.38 | 5.59 | |||
| Pola-R-CHP | 45712.43 | 14697.04 | 5.88 | 0.29 | 51106.77 |
| Different utility | |||||
| R-CHOP | 31015.38 | 6.12 | |||
| Pola-R-CHP | 62819.42 | 31804.04 | 6.41 | 0.29 | 109818.94 |
| Asia subpopulation | |||||
| R-CHOP | 33671.94 | 5.18 | |||
| Pola-R-CHP | 65421.34 | 31749.41 | 5.86 | 0.67 | 47105.46 |
Abbreviations: Pola-R-CHP, polatuzumab vedotin in combination with rituximab, cyclophosphamide, doxorubicin, and prednisone; R-CHOP, rituximab plus cyclophosphamide, doxorubicin, vincristine, and prednisone; C, cost; E, effectiveness; Incr C, Incremental Cost; Incr E, Incremental Effectiveness; ICER, Incremental Cost-Effectiveness Ratio.